OVIT (OncoVista Innovative Therapies) Forward PE Ratio: 0.00 (As of Jul. 03, 2026)


What is OncoVista Innovative Therapies Forward PE Ratio?

OncoVista Innovative Therapies OVIT Forward PE Ratio is 0.00 as of Jul. 03, 2026.

OncoVista Innovative Therapies's Forward PE Ratio for today is 0.00.

OncoVista Innovative Therapies's PE Ratio without NRI for today is 0.00.

OncoVista Innovative Therapies's PE Ratio (TTM) for today is 0.00.

OncoVista Innovative Therapies  (OTCPK:OVIT) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

OncoVista Innovative Therapies Forward PE Ratio Related Terms

OncoVista Innovative Therapies Forward PE Ratio Historical Data

* Premium members only.

The historical data trend for OncoVista Innovative Therapies's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoVista Innovative Therapies Forward PE Ratio Chart

OncoVista Innovative Therapies Annual Data
Trend
Forward PE Ratio

OncoVista Innovative Therapies Quarterly Data
Forward PE Ratio

OVIT vs RSPI, HSTC, CAPS: Forward PE Ratio Comparison

For the Biotechnology subindustry, OncoVista Innovative Therapies's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OncoVista Innovative Therapies Forward PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoVista Innovative Therapies's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where OncoVista Innovative Therapies's Forward PE Ratio falls into.


OncoVista Innovative Therapies Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Frequently Asked Questions Learn more about Forward PE Ratio →
What does a Forward PE Ratio of 0.00 mean?
OncoVista Innovative Therapies (OVIT) has a Forward PE Ratio of 0.00 as of Jul. 03, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on OncoVista Innovative Therapies and its competitors.
Is OncoVista Innovative Therapies' Forward PE Ratio too high?
OncoVista Innovative Therapies' current Forward PE Ratio is 0.00.
How does OncoVista Innovative Therapies' Forward PE Ratio compare to RSPI and HSTC?
OncoVista Innovative Therapies' Forward PE Ratio of 0.00 can be compared against companies in the Biotechnology industry. The industry median Forward PE Ratio is 22.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 22.47, based on 355 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on OncoVista Innovative Therapies and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 22.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OncoVista Innovative Therapies's current Forward PE Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoVista Innovative Therapies stock overvalued right now?
OncoVista Innovative Therapies (OVIT) has a current Forward PE Ratio of 0.00. The current Forward PE Ratio is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For OncoVista Innovative Therapies (OVIT), the current Forward PE Ratio is 0.00 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OncoVista Innovative Therapies Business Description

Address 14785 Omicron Drive, Suite 104, San Antonio, TX, USA, 78245
OncoVista Innovative Therapies Inc is a biopharmaceutical company. It is engaged in developing anticancer therapies by utilizing tumor-associated biomarkers.